24 June 2024
Directa Plus plc
("Directa Plus", the "Group" or the "Company")
Update on Voting & Action to be Taken
Directa Plus (AIM: DCTA) a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, provides an update on the importance of the vote at the upcoming General Meeting to approve the Fundraise announced on 11 June 2024, pursuant to which the Company has, subject to shareholder approval, raised gross proceeds of approximately
As outlined in the Circular, in the event that all the Resolutions are not passed, Admission will not occur and the Company will not receive the funds from the Placing or the Subscription, which would limit the amount of working capital available to the Company. There is no certainty that other funding would be available on suitable terms or at all. Accordingly, in light of the Group's cash position, it would be likely that the Company would have to severely restrict its costs, potentially impacting its ability to progress its growth strategy and generate value for the Group.
The Company has been notified that certain existing shareholders, with a combined shareholding of approximately 19.82 per cent. of the Company, intend to vote against the Resolutions. The Board believes this action jeopardises the future viability of the business and will have a material adverse effect on the Group's business, financial condition, prospects, capital resources, cash flows, share price, liquidity, results and/or future operations. Accordingly, the Board will have no alternative but to seek other, emergency, forms of funding (which, if available, may be on terms significantly less favourable to the Company and its Shareholders) or to take steps to preserve and maximise value for its creditors.
Accordingly, the Board reiterates its unanimous recommendation that all Shareholders vote in favour of the Resolutions.
The General Meeting to approve the Resolutions is expected to be held at the offices of Vistra, 7th Floor, 50 Broadway,
Shareholders are required to vote in favour of the resolutions for the Fundraise to proceed and have until 2.30 p.m. on 25 June 2024 to submit valid Forms of Proxy.
To be valid, a Proxy Vote must be received by the shareholder portal at www.signalshares.com, via the LinkVote+ app, in the case of shares held through CREST, via the CREST system or, if you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform. If you wish to receive a hard copy form of proxy, you may request one directly from the Registrars, Link Group, using the contact details provided in Note 5 to the Notice of the General Meeting.
Please Note: Nominees and Brokers may have earlier internal deadlines, therefore it is recommended that all Shareholders lodge their instructions as early as possible in order to assure their vote is placed on time.
Capitalised terms not otherwise defined in the text of this Announcement have the meanings given in the Circular published on 11 June 2024.
For further information, please contact:
Directa Plus plc |
+39 02 36714458 |
Giulio Cesareo, CEO |
|
Giorgio Bonfanti, CFO |
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 131 220 6939 |
Neil McDonald |
|
Adam Rae |
|
|
|
Singer Capital Markets Securities Limited (Joint Broker) |
+44 20 7496 3069 |
Rick Thompson |
|
Phil Davies |
|
|
|
Alma Strategic Communications (Financial PR Adviser) |
+44 20 3405 0205 |
Justine James |
directaplus@almastrategic.com |
Hannah Campbell |
|
Kinvara Verdon |
|
The person responsible for arranging the release of this Announcement on behalf of the Company is Giorgio Bonfanti, Chief Financial Officer of the Company.
Notes to Editors
Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.
This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, nontoxic product, without unwanted by-products.
Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+(R)) have multiple applications due to its properties. These G+(R) products can be categorised into various families, with different products being suitable for specific practical applications.
Directa Plus was established in 2005 and is based in Lomazzo (
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.